TMAO Lab Test: Normal Range vs. Functional Optimal Levels
Trimethylamine N-oxide (TMAO) is a small molecule produced by gut bacteria and finished in the liver, not a drug or a supplement. It is measured on a blood test, most often by liquid chromatography-tandem mass spectrometry (LC-MS/MS), and it is not part of a routine metabolic panel. This article is about how to read a TMAO result, not about diagnosing or treating any individual reader.
This article requires editorial and qualified clinical review before publication. It has not yet received that review.
The direct answer
A standard laboratory "normal" TMAO result and the lower level associated with the best cardiovascular outcomes in research cohorts are not the same number. Commercial labs typically flag TMAO as elevated only above a single-digit micromolar cutoff derived from population distribution, while several prospective cardiovascular cohort studies have found that participants in the lowest quartile of TMAO (roughly under 2 µM in those cohorts) had measurably fewer cardiac events than those in higher quartiles, including some participants whose values were still inside the "normal" lab range. This gap is real and worth understanding, but the exact cutoffs vary by assay, by cohort, and by kidney function, so no single number should be treated as a universal target. Readers should treat any specific numeric threshold quoted here as a research signal to discuss with a clinician, not a diagnostic line.
What TMAO is and where it comes from
TMAO is generated through a two-step, gut-to-liver pathway. Intestinal bacteria convert dietary choline, L-carnitine, and betaine (found in red meat, egg yolks, some fish, and certain supplements) into trimethylamine (TMA). TMA travels through the portal circulation to the liver, where the enzyme flavin-containing monooxygenase 3 (FMO3) oxidizes it into TMAO, which then circulates in plasma and is cleared largely by the kidneys.
The reason clinicians and researchers have taken interest in this pathway is a body of observational and mechanistic research, beginning with work from a Cleveland Clinic research group in the early 2010s, linking higher circulating TMAO to markers of atherosclerosis and to cardiovascular events in cohorts undergoing evaluation for heart disease. Multiple later cohort studies and meta-analyses have reported similar associations between higher TMAO and higher rates of major adverse cardiovascular events and all-cause mortality. This is observational, association-based evidence. It has not been shown in a large randomized trial that lowering TMAO itself, independent of the dietary and lifestyle changes that lower it, reduces cardiovascular events.
Standard reference range versus the lower range seen in low-risk cohorts
Most commercial and reference laboratories report TMAO using a population-derived reference interval, with an upper limit commonly cited in the single-digit micromolar range. A 2025 multicenter study set out to establish a validated plasma reference interval for TMAO in healthy adults using a standardized assay kit, which is the kind of primary methodological work that should anchor future "normal range" claims (Plasma reference interval of TMAO in healthy adults, 2025). Readers and editors should verify the exact interval reported in that study before publishing a specific numeric cutoff, because assay methods and study populations differ and older secondary sources have circulated numbers that do not consistently trace back to a validated primary source.
Separately, several cardiovascular outcome cohorts (including angiography-based cohorts and long-running population studies) have reported that the lowest-risk group for cardiovascular events was the lowest quartile of measured TMAO, a value that has been described in the literature as under roughly 2 µM in some cohorts. Participants with mid-range TMAO, values that would be reported as "normal" on a standard lab report, have in some of these analyses still shown higher subclinical atherosclerosis burden than the lowest-quartile group. This is the basis for describing a "functional optimal" range that sits below the standard lab cutoff. It is a research-derived pattern from observational cohorts, not an established clinical treatment target endorsed by a cardiology or endocrinology guideline body. Verification against the original cohort papers is needed before any single number is presented to readers as authoritative.
What is established, what is plausible, and what is not established
Established: TMAO is produced by a gut-bacteria-to-liver pathway from choline, carnitine, and betaine; it is cleared primarily by the kidneys; and multiple observational cohorts have found an association between higher plasma TMAO and higher rates of cardiovascular events and mortality.
Plausible but not proven: That a specific low numeric target (such as under 2 µM) is a treatment goal that, if reached through diet or supplements, causally reduces a given patient's cardiovascular risk. The cohort data show association at the population level; it has not been demonstrated in an interventional trial that driving an individual's TMAO down produces a proportional reduction in that person's risk, independent of the dietary changes used to lower it.
Not established: That TMAO should be used as a standalone screening or monitoring test outside of research or specialist cardiovascular risk assessment, that a single reference range applies across all kidney function levels, or that raising a low TMAO level (in someone without trimethylaminuria) provides any health benefit.
Why kidney function changes the interpretation
The kidneys clear the large majority of circulating TMAO, so estimated glomerular filtration rate (eGFR) is a necessary companion value whenever TMAO is interpreted. Patients with chronic kidney disease can have substantially elevated TMAO not because they are overproducing it, but because they are clearing it more slowly. Research cohorts have also reported that elevated TMAO is itself associated with a higher incidence of kidney function decline, which raises the possibility of a bidirectional relationship rather than a one-way cause. For anyone with reduced kidney function, a single TMAO cutoff intended for a healthy population should not be applied without adjustment, and trending the value over time is more informative than comparing it against a fixed threshold.
What changes TMAO levels
TMAO is not fixed; it responds to diet and to the composition of gut bacteria.
Red meat and carnitine. Diets high in red meat and in carnitine supplements are the most consistently reported dietary drivers of higher TMAO in controlled feeding studies, and levels have been reported to fall again after red meat is removed from the diet. Energy drinks and supplements containing added L-carnitine are a commonly overlooked source.
Eggs are a more nuanced case than headlines suggest. Some controlled studies of moderate egg consumption (roughly two eggs daily over several weeks) did not find a significant rise in fasting TMAO, a finding attributed to choline from eggs being substantially absorbed in the small intestine before reaching TMA-producing colonic bacteria. This is a more favorable picture for eggs specifically than for carnitine-rich meat sources, though individual variation in gut microbiome composition means this does not apply uniformly to everyone.
Gut microbiome composition. Certain bacterial genera are more efficient TMA producers than others, which is one reason two people eating similar diets can have different TMAO levels. Fiber and resistant starch intake, a Mediterranean-style dietary pattern with olive oil, and specific studied probiotic strains have each been reported in small trials to lower TMAO, though sample sizes in this literature are frequently modest and strain-specific or trial-specific results should not be generalized to "probiotics" as a category.
Any reader considering a specific supplement (such as a probiotic strain, DMB, or allicin) for this purpose should understand that most of this evidence comes from small human trials or preclinical work, not large randomized outcome trials, and should discuss any supplement with a clinician, particularly if they take other medications or have kidney disease.
Very low TMAO is not itself a problem
TMAO levels near the low end of the range have sometimes been flagged on functional-medicine style panels as a marker of "inadequate choline intake." There is no published outcome data showing that low TMAO causes harm; the cohort literature consistently associates lower TMAO with lower, not higher, cardiovascular event rates. Choline deficiency is a real and distinct clinical entity, but it is diagnosed through direct plasma choline testing and clinical findings such as liver enzyme abnormalities, not through a low TMAO result.
The one clinically important exception is trimethylaminuria (fish odor syndrome), a rare inherited FMO3 deficiency in which the liver cannot convert TMA to TMAO. Affected individuals accumulate TMA instead, producing a characteristic body odor. This is a distinct, uncommon condition diagnosed clinically and confirmed by genetic testing, not something inferred from a routine low TMAO value on a screening panel.
Practical testing considerations
TMAO requires LC-MS/MS and is offered through specialty and reference laboratories rather than as part of a standard chemistry panel. A recent high-choline or high-carnitine meal, or recent carnitine supplement use, can transiently raise a result, so fasting of roughly 8 to 12 hours and avoiding carnitine supplements beforehand is commonly recommended by labs offering the test, though readers should follow the specific instructions of the ordering lab.
Because gut microbiome composition takes weeks to shift meaningfully in response to diet, retesting sooner than about 8 weeks after a dietary change is likely to understate any effect; a recheck window in the range of 3 months is more informative for tracking a dietary intervention.
Out-of-pocket cost and insurance coverage for TMAO testing vary by lab and by payer and change over time; a reader should confirm current pricing and coverage directly with the ordering lab rather than relying on a fixed figure here.
Who this test is realistically useful for
TMAO is not a general population screening test. It has been discussed in the research and clinical literature as a potential adjunct for patients with cardiovascular disease that is not fully explained by traditional risk factors, patients with chronic kidney disease (where it should be interpreted alongside eGFR), and patients on high-dose carnitine supplementation. Any use of TMAO to guide an individual's care, rather than as a research or general-interest data point, should involve a clinician who can weigh it against the person's full risk profile, including lipids, blood pressure, inflammatory markers where relevant, and kidney function.
Decision guide: does the "functional optimal" TMAO framing apply to you?
| Reader situation | Standard lab "normal" range | Does the sub-2 µM research target likely apply? | What actually drives the decision |
|---|---|---|---|
| Healthy adult, no cardiovascular disease, normal kidney function, screening out of curiosity | Usually reported as normal | Interesting context, not an actionable target on its own | Population reference intervals, not outcome data, should guide interpretation; discuss with a clinician before acting on a single number |
| Established atherosclerotic cardiovascular disease not fully explained by LDL, blood pressure, or smoking history | May be normal or elevated | The lower research-associated range is more relevant context here | This is the population where TMAO has been studied as an adjunct risk marker; interpretation needs a clinician managing overall risk |
| Chronic kidney disease (eGFR under 60) | Often elevated regardless of diet | No; a fixed low target is likely unrealistic and clearance, not production, may dominate the number | Trend the value over time rather than compare to a single cutoff; always pair with eGFR |
| Regular high-dose L-carnitine or choline supplement user | May be elevated | Relevant as a monitoring signal for supplement effect | Consider whether the supplement is necessary; a clinician can weigh benefits against a rising TMAO trend |
| Plant-predominant or vegan diet, no cardiovascular disease | Usually low or very low | Likely already near or below the lower research range | No action needed; there is no evidence that raising a low TMAO provides benefit |
| Suspected trimethylaminuria (fish odor syndrome) | May show unusually low TMAO with high TMA | Not applicable; this is a distinct diagnosis | Needs clinical evaluation and genetic testing, not TMAO trend monitoring |
This table is a general framework for discussion with a clinician. It does not replace individualized medical evaluation, and it does not establish dosing, treatment, or diagnostic thresholds for any specific person.
Questions readers actually ask
Is a TMAO result inside the lab reference range always reassuring? Not necessarily. Several cardiovascular cohort studies have reported higher event rates in mid-range TMAO groups compared with the lowest-quartile group, even though both groups would be reported as "normal" by a standard lab. This is a pattern seen in observational research, not a guideline-endorsed treatment threshold.
Should everyone try to get their TMAO under a specific number? There is no professional guideline recommending a universal TMAO target for the general population. The lower ranges discussed in research cohorts describe the group with the fewest cardiovascular events in those studies; they are not an established clinical treatment goal, and pursuing an aggressive numeric target without professional guidance is not supported by current evidence.
Do eggs raise TMAO the way red meat does? The evidence is more reassuring for moderate egg intake than for red meat or carnitine supplements, based on controlled studies showing no significant rise in fasting TMAO with moderate egg consumption, though individual gut microbiome differences mean this will not hold identically for everyone.
If my TMAO is low, should I do anything? Generally no. Low TMAO has not been linked to harm in the outcome literature. The one exception, trimethylaminuria, is a distinct diagnosis with its own clinical presentation and testing pathway, not something inferred from a low value on a routine panel.
When to seek care rather than self-manage
TMAO testing and interpretation should happen in the context of a broader cardiovascular or renal evaluation. A reader with chest pain, unexplained shortness of breath, or other acute cardiac symptoms should seek urgent medical care rather than waiting on a specialty lab result. A reader considering supplements, dietary changes for a diagnosed cardiovascular or kidney condition, or interpretation of an already-elevated result should do so with a treating clinician who has the full clinical picture, not from a lab report or an article alone.
References
- Plasma reference interval of Trimethylamine-N-oxide in healthy adults: A multicenter study using Trimethylamine-N-oxide assay kit for analysis and validation (2025). https://pubmed.ncbi.nlm.nih.gov/40032200/
Other claims in this article describing cohort studies (including the original Cleveland Clinic TMAO-cardiovascular work, later meta-analyses, angiography cohorts, dietary feeding studies, and microbiome composition studies) are described in general terms because the specific identifiers previously attached to them could not be verified against the correct source papers at the time of this draft. Before publication, each of these claims needs to be checked against and, where supportable, linked to its correct primary source.